Fisher Scientific International
This article was originally published in The Gray Sheet
Executive SummaryFiles registration statement with the Securities and Exchange Commission relating to a proposed offering of $125 mil. in step-up convertible subordinated notes due in 2003. The research and testing product manufacturer plans to use $40 mil. of anticipated proceeds to repay outstanding debt related to its Dec. 31 acquisition of the Hamilton Division of Hamilton Industries; the division manufactures laboratory systems and equipment. The balance of proceeds will be used for general corporate purposes, "including working capital, capital expenditures and potential acquisitions." Underwriting the offering are The First Boston Co.; BT Securities; Donaldson, Lufkin & Jenrette; Lazard Freres; and Smith Barney, Harris Upham.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Roughly 18.5% of patients who received reinterventions to fix mesh implants for pelvic organ prolapse (POP) repair experienced complications they will likely endure for the rest of their lives, and they also face a 2.5% higher rate of further surgeries than non-mesh patients, says a recent 54,194-woman study detailed in Obstetrics & Gynecology. The study authors lay out a case that the US FDA should have forced removal of mesh from the market sooner.
HAL Allergy Group, developer of products for allergy diagnostics and allergen immunotherapy, promoted its principal scientist to chief R&D officer; Starkey Hearing Technologies brought on new health and business development execs to expand its global footprint; and more.